Longevity Marketcap Telemetry (March 23nd, 2021)

1. Last Week in Longevity

2. Longevity Futures

3. Capital Raise Radar

4. Longevity Jobs

5. Tweet of the Week

*Disclaimer: None of this should be taken as financial advice. It is for educational purposes only.

**Resources: Longevity Clinical Trial Tracker // Longevity Industry Database. If you are a longevity company, investor, VC firm, fund, non-profit, and want to be added to the database please email me. It’s free.

***Fundraising If you know of anything that indicates longevity companies that are currently looking for funding please email me. I will add them to the “Fundraising Radar” section of the newsletter and database. It’s free.

**** Hiring? Email me the links to your job postings and I will put them on LongevityList.com (and select jobs in this newsletter). It’s free.

📢 Announcements 

• The 1% Bet for Longevity-- a website initiative. Building on my newsletter last week and a suggestion from one of my readers, Matthew Busel, I have launched the 1% Bet for Longevity. The initiative seeks to convince as many people as possible to publicly promise to commit at least 1% of their net worth towards funding longevity biotechnology companies or research. Longevity biotechnology holds the potential for incredible upside. And yet despite this much less than 1% of the $400T total global wealth has been directed towards longevity.
  
  I want to change this --and I am going to start by leading by example. You can stand up for longevity too by going to the website onepercentbet.org and submitting your name on the form. Your name will be added to the public list of signatories after moderation.
  
  Isn’t more life worth more betting on? Spread the word.

• PS: I have a Patreon account. My mission is to grow a wave of passionate people building, funding, and championing technologies that extend healthy human lifespan. If you believe in me, my work, and my mission please consider supporting.

📝 Last Week in Longevity

• BioAge announces the launch of their 2nd clinical trial --reversing immune system aging in COVID-19 patients. AI/ML drug discovery startup BioAge has officially begun its trial of BGE-175 for COVID-19 patients over the age of 60. BGE-175 is a small molecule antagonist of the prostaglandin D2 DP1 receptor, which regulates immune function. BGE-175 is a drug licensed from Shionogi, a Japanese pharma company. Top-line data from the